WRBY
Warby Parker Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$24.12
+3.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 911.6M | 871.9M | 771.3M | 669.8M | 598.1M |
| Cost of Revenue | 413.1M | 401.3M | 344.5M | 304.5M | 257.1M |
| Gross Profit | 498.5M | 470.6M | 426.8M | 365.2M | 341.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 363.6M | 475.9M | 440.1M | 421.6M | 452.3M |
| General & Admin Expense | — | — | 344.3M | 345.5M | 375.4M |
| Selling & Marketing Expense | — | — | 95.8M | 76.1M | 76.9M |
| Other Expenses | 133.3M | — | 16.9M | 15.6M | — |
| Total Operating Expenses | 496.9M | 475.9M | 456.9M | 437.2M | 452.3M |
| Cost and Expenses | 910.1M | 877.2M | 801.4M | 741.8M | 709.3M |
| Operating Income (EBIT) | 1.6M | (5.3M) | (30.1M) | (72.0M) | (111.2M) |
| Non-Operating | |||||
| Interest Income | 6.3M | 8.4M | 10.6M | 9.2M | 1.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 6.3M | 8.4M | 10.6M | 9.2M | 1.3M |
| Other Non-Op Income/Expense | 8.4M | 8.4M | 10.6M | 9.2M | 1.3M |
| Non-Operating Income (excl Interest) | (8.4M) | (8.4M) | (10.6M) | (9.2M) | (1.3M) |
| EBT (Pre-Tax Income) | 9.9M | 3.0M | (19.5M) | (62.8M) | (109.9M) |
| Income Tax Expense | 2.2M | 1.4M | 875.0K | 433.0K | 497.0K |
| Bottom Line | |||||
| Net Income | 7.7M | 1.6M | (20.4M) | (63.2M) | (110.4M) |
| Earnings from Cont. Ops | 7.7M | 1.6M | (20.4M) | (63.2M) | (110.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 7.7M | 1.6M | (20.4M) | (63.2M) | (110.4M) |
| Per Share | |||||
| Basic EPS | $0.07 | $0.01 | ($0.17) | ($0.54) | ($0.96) |
| Diluted EPS | $0.07 | $0.01 | ($0.17) | ($0.54) | ($0.96) |
| Revenue Per Share | $7.36 | $7.11 | $6.41 | $5.71 | $5.20 |
| Shares | |||||
| Basic Shares Outstanding | 123.9M | 122.7M | 120.4M | 117.4M | 114.9M |
| Diluted Shares Outstanding | 125.7M | 125.1M | 120.4M | 117.4M | 114.9M |
| Profitability Metrics | |||||
| EBITDA | 79.2M | 53.3M | 26.4M | (24.2M) | (78.0M) |
| D&A | 69.3M | 50.3M | 45.9M | 38.6M | 31.9M |
| EBIT | 9.9M | 3.0M | (19.5M) | (62.8M) | (109.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026